Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab

Onur Cetin, Igor Age Kos, Evi Regitz et al. Nov 03, 2025 pp. 1750-1750 10.1182/blood-2025-1750

Abstract INTRODUCTION Rituximab mediated antibody-dependent cellular cytotoxicity (ADCC) is an essential component of th...

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Eshrak Al-Shaibani, Jonas Mattsson, Yu Cai et al. Nov 03, 2025 pp. 4273-4273 10.1182/blood-2025-4273

Abstract Introduction Post-transplant maintenance (PTM) therapy with tyrosine kinase inhibitors (TKIs) is increasingly u...

Chemotherapy-related toxicities and healthcare burden in Acute Myeloid Leukemia: A nationwide inpatient analysis

Samhitha Gundakaram, SWAPNA SIRIGIREDDY, Imtisaal Waris et al. Nov 03, 2025 pp. 8196-8196 10.1182/blood-2025-8196

Abstract Background: Acute myeloid leukemia (AML) therapy remains heavily reliant on cytotoxic regimens that carry a substantial risk of sys...

The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Colleen Kelly, Morgan Paul, Wendy London et al. Nov 03, 2025 pp. 6224-6224 10.1182/blood-2025-6224

Abstract Introduction: Gene therapy offers a transformative, potentially curative opportunity for patients with sickle cell disease (SCD), a...

Computational immunophenotypic profiling of multiple myeloma by flow cytometry and bioinformatics integration

Áyslla Martins, Ian Bahia, Francisco Lima et al. Nov 03, 2025 pp. 2244-2244 10.1182/blood-2025-2244

Abstract Introduction: Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone m...

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Zachary Hunter, Amanda Kofides, Abigail Peachey et al. Nov 03, 2025 pp. 3544-3544 10.1182/blood-2025-3544

Abstract Background: We previously developed a quasi-Poisson model to predict background coverage of intron segments with deviations from pre...

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

Jason Gilbert, Megan Othus, Suravi Raychaudhuri et al. Nov 03, 2025 pp. 1677-1677 10.1182/blood-2025-1677

Abstract Background: Nucleoside reverse transcriptase inhibitors (NRTIs) are integral to therapy for human immunodeficiency virus (HIV) and...

Defining a high-risk population for CAR-T-cell therapy: The impact of clonal hematopoiesis and pre-existing neutropenia on severe outcomes in patients treated for malignant and non-malignant conditions

Alisha Weiss-Haug, Reka Haraszti, Jan Christian Schroeder et al. Nov 03, 2025 pp. 5942-5942 10.1182/blood-2025-5942

Abstract Importance: CAR-T cells show high efficacy in B-cell neoplasia and non-malignant B-cell driven autoimmune disorders, but therapy-re...

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Shayna Sarosiek, Mary Kwok, Prashant Kapoor et al. Nov 03, 2025 pp. 581-581 10.1182/blood-2025-581

Abstract Introduction: Waldenström macroglobulinemia (WM) is characterized by the presence of a MYD88 mutation in >90% and a CXCR4 mu...

MGUS like phenotype in patients with AL amyloidosis: Impact on clinical outcomes for patients treated with bortezomib-containing regimens (BCR).

Victor Jimenez-Zepeda, Etienne Mahe, Sylvia McCulloch et al. Nov 03, 2025 pp. 3963-3963 10.1182/blood-2025-3963

Abstract Multiple Myeloma and Light-chain (AL) amyloidosis are clonal plasma cell disorders with different clinical expressions. Recently, B...

Patient-reported quality of life in Chinese children with B-cell acute lymphoblastic leukemia receiving first-line treatment with blinatumomab

Jia Fan, Mengjia Liu, Peijing Qi et al. Nov 03, 2025 pp. 1551-1551 10.1182/blood-2025-1551

Abstract Objective: This study aims to evaluate patient-reported quality of life (QoL) in children with Ph-negative B-cell acute lymphoblast...

T follicular helper cells are mis-localized in idiopathic multicentric castleman disease

Melanie Mumau, Katherine Forsyth, Michael Gonzalez et al. Nov 03, 2025 pp. 1236-1236 10.1182/blood-2025-1236

Abstract Idiopathic multicentric Castleman disease (iMCD) is an atypical hematologic disorder with significant morbidity and mortality. Defi...

Clinical characteristics and prognosis of 197 pediatric patients with refractory cytopenia: A single-center retrospective analysis

Zixi Yin, Wenbin An, Chenmeng Liu et al. Nov 03, 2025 pp. 2088-2088 10.1182/blood-2025-2088

Abstract Refractory cytopenia of childhood (RCC) is a common subtype of pediatric MDS characterized by variable degrees of cytopenias, &...

Outcomes after bone marrow versus peripheral blood matched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based gvhd prophylaxis

Amna Bint I Munir, Aqeeb Ur Rehman, Moazzam Shahzad et al. Nov 03, 2025 pp. 6024-6024 10.1182/blood-2025-6024

Abstract Background: Post-transplant cyclophosphamide (PTCy) has emerged as a prevalent strategy for preventing graft-ve...

Elevated relative risk of venous thrombosis in young adults with colorectal cancer: A global retrospective study

Shreyashree Sarkar, Srija Sivamurugan, Izola Ramalho et al. Nov 03, 2025 pp. 707-707 10.1182/blood-2025-707

Abstract Colorectal cancer (CRC) is a major global health concern, with an annual incidence of 35.9 per 100,000 and a mortality rate of 13.1...

Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age

Aqeeb Ur Rehman, Moazzam Shahzad, Shah Rukh et al. Nov 03, 2025 pp. 5985-5985 10.1182/blood-2025-5985

Abstract Background High-dose melphalan (140 mg/m²) followed by autologous hematopoietic cell transplantation (auto-HCT) is a standard conso...

Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in Acute Myeloid Leukemia

Saurabh Kumar Gupta, Kazuharu Kamachi, Liang Zhang et al. Nov 03, 2025 pp. 1496-1496 10.1182/blood-2025-1496

Abstract Resistance to apoptosis remains a major clinical challenge in acute myeloid leukemia (AML), especially in relapsed/refractory (R/R)...

A prospective pilot study integrating health care coaching into VA hematologic cancer care: A VA-leukemia & lymphoma society (LLS) collaborative initiative

Mark Rudolph, Aliecia Hochhausler, Catherine Robson et al. Nov 03, 2025 pp. 2797-2797 10.1182/blood-2025-2797

Abstract Background: Veterans diagnosed with hematologic disorders, including multiple myeloma (MM), monoclonal gammopathy of undetermined s...

Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis

Mauricio Saldana Ruiz, Michelle Morcos, Victor Castillo et al. Nov 03, 2025 pp. 6475-6475 10.1182/blood-2025-6475

Abstract Introduction Beta thalassemia is an inherited blood disorder caused by mutations in the genes encoding beta globin. In transfusion-...

Irregulab: Automated interpretation of irregular antibody panels

Davide Crucitti, Violeta Vidal Ballester, Jesús Gómez Fernández et al. Nov 03, 2025 pp. 6160-6160 10.1182/blood-2025-6160

Abstract Introduction Identifying irregular red-cell antibodies is an essential but still largely manual task in transfusion medicine. Inter...

Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.

Yasser Khaled, Juan Varela, Samer Khaled et al. Nov 03, 2025 pp. 4196-4196 10.1182/blood-2025-4196

Abstract Post-transplant cyclophosphamide (PTCy) at the standard dose of 50 mg/kg on D+3 and +4 has evolved as the backbone for graft-versus...

Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia

Xiaofang Ma, Minghao Jiang, Jin Wang et al. Nov 03, 2025 pp. 1585-1585 10.1182/blood-2025-1585

Abstract Background Acute lymphoblastic leukemia (ALL) is the most prevalent malignant tumor among children and adolescents, with poor progn...

Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact cosi trial

Charles Craddock, Graham Mcllroy, Hannah Vincent et al. Nov 03, 2025 pp. 110-110 10.1182/blood-2025-110

Abstract Purpose:Disease relapse remains the major cause of treatment failure in patients allografted for acute myeloid leukaemia (AML) and...

Non-genotoxic conditioning to increase donor chimerism levels in a mismatched murine transplant model for sickle cell disease

Mohamed Ali, Cynthia Joseph, Deanna Gaskin et al. Nov 03, 2025 pp. 5858-5858 10.1182/blood-2025-5858

Abstract Sickle cell disease (SCD) can lead to acute complications, chronic organ damage, and early mortality. The only cure for SCD is a he...

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Colin Thomas, Jina Chung, Daniel Landsburg et al. Nov 03, 2025 pp. 560-560 10.1182/blood-2025-560

Abstract Introduction: Sézary Syndrome (SS) is an aggressive variant of cutaneous T-cell lymphoma involving diffuse erythroderma (T4) and le...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page